Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.
And let's not forgot the Canrenoate option. We published some rescue cases https://t.co/SVejeVvYNG
Actually I learn cardiology like that in Lyon, IV furosemide and 200 mg of IV canrenoate 2 to 3 times a day. Published only recently here https://t.co/zoU8zjPZYT https://t.co/40dCFXWXh7